MANNKIND CORP
MannKind (MNKD) shares rose 5.1% after the company reported Q2 2026 revenue of $109.37 million, up from $76.53 million a year earlier, but a net loss of $19.03 million versus a small net profit. MannKind also released positive Phase 1b inhaled nintedanib DPI safety data for idiopathic pulmonary fibrosis.
MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ aut
MannKind (MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis. In a randomized, double-blind, placebo-controlled trial of 27 patients, it met the primary objective of safety and tolerability, with no serious adverse events, GI effects, bronchospasm, or discontinuations. MannKind is enrolling Phase 2 INFLO-2.
Over the past 7 days, alphai's AI scored 2 news stories mentioning MNKD (MANNKIND CORP). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent MNKD coverage spans regulation, earnings and technology.
In the last 30 days, MNKD insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($311K). The most active reporter was Thomson David, EVP Genl Counsel & Secretary, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Positive early inhaled nintedanib safety data improves the long-term IPF narrative, but the Q2 net loss and ongoing cash burn keep financing risk central.
New FDA approvals and positive MNKD-201 Phase 1b topline data reduce development risk and support near-term commercial ramp for MNKD’s diabetes and HF/CKD franchises.
The safety/tolerability readout reduces near-term clinical risk for MNKD’s nintedanib DPI program and supports progression to Phase 2 INFLO-2.
Positive early safety/tolerability data for MNKD-201 (nintedanib DPI) reduces near-term clinical risk and supports continued Phase 2 enrollment momentum.
Near-term catalyst is the Aug 5 earnings release and call; incremental clinical-support detail may modestly affect sentiment ahead of results.
alphai scores every news story that mentions MNKD with an AI model for sentiment and relevance, and aggregates insider trades from MANNKIND CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
MannKind (MNKD) shares rose 5.1% after the company reported Q2 2026 revenue of $109.37 million, up from $76.53 million a year earlier, but a net loss of $19.03 million versus a small net profit. MannKind also released positive Phase 1b inhaled nintedanib DPI safety data for idiopathic pulmonary fibrosis.
6 min readMANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ aut
4 min readMannKind (MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis. In a randomized, double-blind, placebo-controlled trial of 27 patients, it met the primary objective of safety and tolerability, with no serious adverse events, GI effects, bronchospasm, or discontinuations. MannKind is enrolling Phase 2 INFLO-2.
4 min readMannKind (Nasdaq: MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis. In 27 patients, it met safety and tolerability goals with no serious adverse events, no bronchospasm or diarrhea, and no discontinuations. Phase 2 INFLO-2 is enrolling about 210 patients.
3 min readMannKind Corporation (NASDAQ: MNKD) said it will release Q2 2026 financial results after the market close on Aug. 5, 2026. A conference call is scheduled for 4:30 p.m. ET with a webcast and replay on the company’s investor site. The article also notes a Breakthrough T1D grant supporting the INHALE-1ST Afrezza study in pediatric type 1 diabetes.
4 min readMannKind Corp. said it raised $50 million from institutional investors after the FDA approved Furoscix ReadyFlow, an injectable for adults with heart failure or chronic kidney disease with fluid overload. Proceeds include a $45 million milestone payment tied to MannKind’s 2025 scPharmaceuticals acquisition. MannKind expects US availability by end-August.
3 min readBenzinga reports that the FDA approved MannKind’s at-home treatment option for heart failure or kidney disease. The article also includes a Benzinga Edge scorecard for MannKind, citing weak momentum (41.94) and weak value (12.44), with the stock trading at a premium versus peers.
2 min readMANNKIND CORP (MNKD) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. EX-4.2 3 d63182dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “ Agreement ”), dated as of July 23, 2026, is entered into by and among MannKind Corporation, a Delaware corporation (the “ Company ”), and the several invest
2 min readThe FDA approved MannKind’s Furoscix ReadyFlow, a furosemide injection autoinjector for edema in adults with heart failure or chronic kidney disease. MannKind said it delivers an 80 mg/mL dose in under 10 seconds. The company also announced a private placement of about $50 million to fund general purposes, including a $45 million contingent value rights payment. MNKD shares rose to about $4.16.
4 min readMannKind Corp. (MNKD) said the FDA approved Furoscix ReadyFlow for edema in adults with heart failure or chronic kidney disease, citing clinical data showing IV-equivalent exposure and comparable urine, sodium and potassium outcomes versus IV furosemide. The company plans a U.S. autoinjector launch by end-August 2026. It also announced a $50M private placement at $3.89/share.
4 min read
